A practical guide for transitioning from classical immunosuppressants to dupilumab in atopic dermatitis

Click to increase image sizeClick to decrease image size

Disclosure statement

Vivian Shi is a stock shareholder of Dermveda, has served as an advisor for Sanofi Genzyme/Regeneron, AbbVie, Novartis, Sun Pharma, Pfizer, Menlo Therapeutics, Burt’s Bees, GpSkin, the National Eczema Association and Global Parents for Eczema Research, is an investigator for AbbVie, Regeneron, Novartis, and Leo Pharma, and has received research funding from the Foundation for Atopic Dermatitis and Skin Actives Scientific. There were no incentives or transactions, financial or otherwise, relevant to this manuscript.

Peter Lio has served as an investigator, speaker, advisory board member, and consultant for Sanofi Genzyme/Regeneron. There were no incentives or transactions, financial or otherwise, relevant to this manuscript.

Catherine Ludwig, Kyla Price, and Jeffrey Krase have no potential conflicts of interest to declare.